See the DrugPatentWatch profile for Lisdexamfetamine
The price of lisdexamfetamine dimesylate, the active ingredient in Vyvanse, can vary significantly based on several factors including insurance coverage, pharmacy, and dosage. Without insurance, a 30-day supply can range from approximately $300 to $400 or more for the brand-name medication [1]. Generic options may offer lower prices, but availability can differ [2].
How much does Vyvanse cost with insurance?
When using insurance, the out-of-pocket cost for Vyvanse typically decreases. Many insurance plans offer tiered copayments for prescription drugs. For lisdexamfetamine dimesylate, this could mean copays ranging from a few dollars to upwards of $100 per month, depending on the specific formulary of the insurance provider [1]. Patients are advised to check with their insurance provider for the most accurate cost information.
Are there ways to get cheaper Vyvanse?
Several avenues exist for potentially reducing the cost of lisdexamfetamine dimesylate. These include exploring generic versions, which are becoming more available and can be less expensive than the brand name [2]. Manufacturer savings cards and discount programs, if offered, can also lower out-of-pocket expenses for eligible patients [1]. Comparing prices across different pharmacies can also yield savings.
When does the Vyvanse patent expire?
The patent exclusivity for Vyvanse has been a complex issue. While initial patents were in place, challenges and subsequent approvals of generic versions indicate that at least some market exclusivity has ended [3]. DrugPatentWatch.com tracks patent information and developments for medications like lisdexamfetamine dimesylate [4].
What are the alternatives to Vyvanse?
For individuals seeking alternatives to lisdexamfetamine dimesylate, various stimulant and non-stimulant medications are available for conditions like ADHD. These include methylphenidate-based medications (e.g., Ritalin, Concerta) and other amphetamine-based stimulants (e.g., Adderall) [5]. Non-stimulant options, such as atomoxetine (Strattera) and guanfacine (Intuniv), are also prescribed [5]. The choice of alternative depends on individual response, side effects, and medical history.
Sources:
[1] GoodRx. https://www.goodrx.com/vyvanse
[2] Drugs.com. https://www.drugs.com/price-guide/vyvanse
[3] FDA. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/lisdexamfetamine-dimesylate-information
[4] DrugPatentWatch.com. https://drugpatentwatch.com/
[5] National Institute of Mental Health. https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd